[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

(857) 259-3840

Email address

nmota@jouncetx.com

Condition

Cancer

Treatment type

Interventional

Investigational product

JTX-4014

Phase

Phase 1/Phase 2

Sponsor

Jounce Therapeutics, Inc.

ClinicalTrials.gov identifier

NCT04669899

Study number

JTX-8064-101

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of JTX-8064 alone and in combination with a PD-1 inhibitor (PD-1i).

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site